Covaxin: Indigenous Vaccine for COVID-19
Covaxin is India's first vaccine candidate to have gone into human clinical trials. It is developed by Bharat Biotech and has been approved by the Drug Controller General of India (DCGI) for phase I and II human clinical trials.
- The SARS-CoV-2 strain was isolated in National Institute of Virology (NIV), Pune and transferred to Bharat Biotech. They developed Covaxin as an “inactivated” vaccine — one made by using particles of the Covid-19 virus that were killed, making them unable to infect or replicate. Injecting particular doses of these particles serves to build immunity by helping the body create antibodies against ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 Greening India’s MSMEs: A Roadmap for Clean Industrial Transition
- 2 Renewables as an Employment Engine: India’s Opportunities and Risks
- 3 Global Water Bankruptcy: Living Beyond Our Hydrological Means
- 4 Robust Groundwater Governance: Anchoring India’s Water Security
- 5 Citizen-Centric Healthcare: Pathway to Universal Health Coverage in India
- 6 Reshaping India’s Juvenile Justice Framework
- 7 Biomaterials: Leveraging Eco-friendly Alternatives for a Low-Carbon Economy
- 8 Strategic Autonomy and the UN Charter: Navigating the Venezuela and Greenland Crises
- 9 India-EU Free Trade Agreement: A Strategic Bet on Trade, Talent and Supply Chains
- 10 Urban Wastewater Management: A Crisis and a Call for Reform
